Opus Genetics, Inc. (IRD)
(Delayed Data from NSDQ)
$1.07 USD
-0.04 (-3.60%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.09 +0.02 (1.87%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Opus Genetics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
IRD 1.07 -0.04(-3.60%)
Will IRD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRD
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
IRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Other News for IRD
Opus Genetics (IRD) Partners with Global RDH12 Alliance for Gene Therapy Advancement | IRD ...
Opus Genetics (IRD) Forms Strategic Partnership to Advance Gene Therapy | IRD Stock News
Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IRD Stock News